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ments. The Transactional Model of Stress and Coping was used
as the theoretical framework for the study and self-report data
on diabetes-related stress, views of diabetes, coping and HRQoL
were obtained. The Short-Form 8 (SF-8) was used to measure
HRQoL by determining the overall mental component (MCS)
and physical component scores (PCS). Path analysis via multiple
regression analysis was used to evaluate the relationships pro-
posed in the study model. Age, gender, race, education, marital
status, insurance, smoking, insulin use, body mass index, Charl-
son comorbidity score, history of depression, duration of dia-
betes and HbA1C values were incorporated into the model as
control variables. RESULTS: A total of 217 surveys were col-
lected with a usable response rate of 93%. The mean age of the
overall sample was 57.3 years (SD = 11.9), 62.2% were female
and 61% were Hispanic. High diabetes-related stress was asso-
ciated with a negative view of diabetes (b = 0.60, p < 0.001). A
negative view of diabetes was associated with decreased use of
problem-focused coping (b = -0.23, p < 0.05), increased use of
avoidance (b = 0.32, p < 0.001), passive resignation (b = 0.64,
p < 0.001) and poor diabetes integration (b = 0.57, p < 0.001).
Passive resignation coping was in turn associated with a lower
PCS (b = -0.20, p < 0.01). Lower MCS was associated with
passive resignation (b = -0.21, p < 0.01) and poor diabetes inte-
gration (b = -0.20, p < 0.01). CONCLUSIONS: Passively resign-
ing oneself to diabetes was found to be associated with a lower
PCS and MCS. Poor integration of diabetes into one’s life was
also associated with lower MCS. Stress management and coping
skills training may improve HRQoL in patients with T2DM.
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OBJECTIVES: The measurement of patient compliance to med-
ications in a large database analysis presents inherent challenges,
such as concomitant prescriptions, switches and add-ons. The
Medication Coverage (MC) methodology is an application of the
Medication Possession Ratio (MPR) that allows for considera-
tion of multiple prescriptions simultaneously or serially. The 
beneﬁts of this approach to outcomes research are explored.
METHODS: In 3864 patients with primary open-angle glau-
coma (POAG), a prescription for a glaucoma medication, and a
minimum 2 years of continuous enrollment post-index date (date
of ﬁrst glaucoma therapy) were identiﬁed within the PharMet-
rics database. MC was calculated as the proportion of days a
patient was in possession of any glaucoma medication during the
ﬁrst year of follow-up. Medication possession on each day was
considered as a binomial variable (presence or absence of med-
ication), independent of whether patients were on one or multi-
ple medications. We designated the 75th percentile of the MC
score to stratify patients as “more” versus “less” compliant.
“More Compliant” was then tested as a predictor in multivari-
ate logistic models, while controlling for key covariates, pre-
dicting ocular surgery in year two of follow-up. RESULTS: The
MC methodology applied in this sample data showed that mean
MC was 0.47 and 75th percentile MC was 0.67. Coverage was
normally distributed. Logistic regression models showed that as
severity of POAG patients increases, compliance with pharma-
cotherapies is increasingly associated with a reduced risk of glau-
coma surgery. CONCLUSIONS: MC can be used to examine
patient compliance with medication in large retrospective data-
base analyses. This technique allows for analysis of patient com-
pliance to medication while considering concomitant medica-
tions and various treatment patterns.
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OBJECTIVES: Positive return on investment (ROI) for disease
management (DM) programs has generally been limited to those
managing congestive heart failure or multiple disease conditions.
It is the objective of this model to evaluate the ROI of a glau-
coma-screening DM program in Commercial vs. Senior member
populations. METHODS: An interactive Excel-based 14-year
economic model previously developed to assess the payer costs
associated with screening and early treatment of glaucoma
patients vs. non-screening of asymptomatic progressive disease
was extended to dynamically model the drug treatment compo-
nent. Treatment costs and disease progression rates were taken
from the published literature. Drug costs were based on average
wholesale price cost with consideration of contractual discounts
and patient co-payment. The primary economic endpoint was
the ratio of reduced annual treatment costs compared to annual
program costs. Multi-factor sensitivity analyses were conducted.
RESULTS: In a Commercial population, total annual costs to
“screen and treat” vs. a strategy of no screening was estimated
to be $0.62 PMPM vs. $0.80 PMPM respectively (a difference
of $0.12 PMPM in favor of screening). In the Senior population,
these costs were estimated to be $6.66 PMPM vs. $7.94 PMPM
respectively (a difference of $1.28 PMPM in favor of screening).
With estimated program costs of $0.009 PMPM and $0.167
PMPM in the Commercial vs. Senior populations respectively,
the calculated potential ROI was estimated to be 2.6 and 1.7
respectively for these programs. CONCLUSION: The early iden-
tiﬁcation and treatment of glaucoma in accordance with estab-
lished evidence-based clinical practice guidelines represents a
more cost-effective strategy as compared to non-screening of at
risk populations. Total annual costs for a glaucoma-screening
disease management program are estimated to demonstrate a
positive ROI in both Commercial and Senior populations. These
ﬁndings may help promote the interest of payers in implement-
ing pertinent quality improvement and HEDIS-related efforts.
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OBJECTIVES: To investigate the quality of economic analyses
submitted by pharmaceutical manufacturers to health plans
under the Academy of Managed Care Pharmacy (AMCP) Format
for formulary submissions. To compare quality of economic
analyses between high-cost and other products, and between
“me-too” and other drugs. METHODS: We reviewed all eco-
nomic analyses included in AMCP-Format dossiers submitted by
pharmaceutical companies to Premera Blue Cross (Mountlake
Terrace, WA, enrollment 1.5 million) between January 2002 and
September 2005. Economic analyses were deﬁned as research
studies or mathematical models that combined clinical and cost
